Delivery Order SPE2DB24D9131-SPE2DB24FXRH1
Award Date
4/9/24
Potential Completion Date
4/30/24
Potential Value
$3.1K
Federal Agency
Defense Logistics Agency
Awardee
DMS Pharmaceutical Group Inc.
Ultimate Awardee
Not listed
NAICS Category
424210 - Drugs and Druggists' Sundries Merchant Wholesalers
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Park Ridge, IL 60068, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business. The contract, valued at $3,094.80, is to provide the DLA with 4564570218 - XOLAIR 150 MG/ML SYRINGEML. This order is part of a larger indefinite delivery contract (IDC) with DMS Pharmaceutical Group that has a ceiling value of up to $499,999,999. The IDC, awarded under the DLA's SPE2DB program, allows the agency to issue delivery orders for...
The Defense Logistics Agency (DLA) awarded a firm fixed price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business, for the supply of the pharmaceutical product XOLAIR 150 MG/ML SYRINGE at a potential value of $46,422.00. This order is part of a larger indefinite delivery contract held by DMS Pharmaceutical Group Inc. with DLA to provide a variety of pharmaceutical items and medical supplies to military treatment facilities worldwide. The contract does not have a...
The U.S. Defense Logistics Agency (DLA) awarded a Firm Fixed Price delivery order contract worth $3,094.80 to DMS Pharmaceutical Group Inc., a woman-owned small business. The contract is for the delivery of XOLAIR 150 MG/ML syringes and has a performance period through May 2, 2024. This award is placed against DMS Pharmaceutical Group's existing indefinite delivery contract SPE2DB with DLA, valued at up to $4,999,999 through 2025. Under this broader contract vehicle, DMS Pharmaceutical Group...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order valued at $4,642.20 to DMS Pharmaceutical Group Inc., a woman-owned small business, for the procurement of 4,564,160,403 units of the pharmaceutical product Xolair 150 mg/mL syringe. This order is part of a larger indefinite delivery contract, SPE2DB24FE6SV, with DMS Pharmaceutical Group valued at up to $4,999,999 through 2025. The contract allows DLA to issue delivery orders for a broad range of pharmaceutical...
The U.S. Defense Logistics Agency (DLA) awarded a firm-fixed-price delivery order contract, number SPE2DB24FZB70, to DMS Pharmaceutical Group Inc., a woman-owned small business, to provide XOLAIR 150 MG/ML SYRINGEML. The $18,568.80 order has an ultimate completion date of April 16, 2024. This delivery order is part of a larger indefinite delivery contract, number SPE2DB22D9143, that DMS Pharmaceutical Group holds with DLA, valued at up to $4,999,999 through the end of 2025. The IDC enables DLA...
The Defense Logistics Agency (DLA) awarded a $27,853.20 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, for the supply of Xolair 150 mg/ml syringes. This order is part of a larger $499,999,999 Indefinite Delivery Contract (IDC) held by DMS Pharmaceutical Group with the DLA under the SPE2DB program, which enables the DLA to issue delivery orders for a comprehensive range of pharmaceutical products to support the medical...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business, for the supply of XOLAIR 150 MG/ML SYRINGE. The single-award, firm fixed-price contract has a ceiling value of $37,137.60 and an ultimate completion date of May 3, 2024. This delivery order is placed under DMS Pharmaceutical Group's indefinite delivery contract 4600082013 with the DLA, which has a total potential value of up to $4,999,999 through 2025. The...
The U.S. government agency, the Defense Logistics Agency (DLA), awarded a $11,605.50 firm fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business. The contract is for the provision of XOLAIR 150 MG/ML SYRINGEML, a pharmaceutical product, with a completion date of February 25, 2025. This delivery order is part of a larger Indefinite Delivery Contract (IDC) valued at $499,999,999 that DMS Pharmaceutical Group holds with the DLA under the SPE2DB program....
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business, for the supply of Xolair 150 mg/mL syringes. The contract, valued at $9,284.40, has an ultimate completion date of April 23, 2024. This delivery order falls under DMS Pharmaceutical Group's existing indefinite delivery contract, SPE2DB22D9362, with the DLA worth up to $4,999,999 through the end of 2025. This larger contract enables the DLA...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract valued at $4,642.20 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. This contract is for the supply of XOLAIR 150 MG/ML SYRINGE, a biologic medication, to support the recurring medical needs of military health facilities. The award is part of a larger indefinite delivery contract (IDC) with DMS Pharmaceutical Group valued at up to...